ClinicalTrials.gg
RecruitingNCT04834518ADIRUpdated Oct 17, 2024

Screening for Islet Autoantibodies in the Israeli Paediatric General Population for Detection of Pre-symptomatic Type-1 Diabetes Mellitus

An observational study in Type1diabetes, sponsored by Rabin Medical Center. Recruiting at 7 sites in Israel. Open to participants aged 9 Months to 5 Years. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by Rabin Medical Center · Observational

How we know

From the registry’s dates

  • Started Apr 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50,000
Ages
9 Months to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center — 8 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Rabin Medical Center.

Started
2021
the only one that year
Observational
4 of 42
3 open now
Registered
35th of 42
by date

Among the 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center, this one is the only one that started in 2021, is one of 4 observational ones, and was the 35th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

8 of the 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 9 Months to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center, or all of them as a file.
02

Study summary

A national screening program for children aged 9 months-5 years that will be tested for the presence of islet autoantibodies.Up to 50,000 Children will be screened by their primary care physician all over Israel. The initial screening will be done at the age of 1 year (in conjunction with the routinely collection of blood for CBC ) and repeated at ages 2-5 years. Antibodies will be measured in capillary blood samples using the Ultrasensitive Antibody Detection by Agglutination-PCR (ADAP) technology developed by Enable Biosciences, which is 1,000-10,000 times more analytically sensitive than currently used methods. By using this innovative technology in such a large cohort, the study is anticipated to detect antibodies at an unprecedented earlier age.When positive in the screening, multiple antibodies will be confirmed by a second sample analyzed by the ADAP technology. In addition, multiple antibodies will be also measured using a radio-binding assay (RBA) of a venous blood sample for investigational purpose only. Children with confirmed multiple antibodies (stage 1 or 2 T1D) will be followed up routinely for the appearance of clinical signs of diabetes (HbA1c, repeated OGTT, monitoring of urine and blood glucose where indicated) and will be invited along with their families to attend an educational program. This program will include diabetes education emphasizing on DKA prevention as well as stress assessment for the families involved and stress alleviating interventions. The analysis and storage of the samples will be done in a single screening center at Schneider Children's Medical Center of Israel.

03

Conditions studied

  • Type1diabetes

Keywords

  • autoantibodies screening
04

Who can participate

Ages eligible
9 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children from the general population of all over Israel, aged 9 months-5 years arriving to the routine blood test for CBC or to any other routine visit to the community pediatrician.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities
  • Children aged 9-months- 5 years at first screening.

Exclusion criteria

Exclusion Criteria:

  • Known diagnosis of diabetes (Type 1 or other)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Negative result at the first autoantibodies screening test

    Participants will be invited to repeat the screening test at the age of 2-5 years old

  • Positive result at the first or second autoantibodies screening test

    * Participants will be monitored annually for risk of type 1 diabetes. (HbA1c, repeated OGTT, monitoring of urine and blood glucose where indicated) * Families will attend diabetes-educational program emphasizing on DKA prevention * Stress assessment for the families involved and stress alleviating interventions when required.

06

What researchers measure

Primary outcomes

  1. Diagnosis of presymptomatic type 1 diabetes

    Presymptomatic type 1 diabetes, defined as positive for 2 or more islet autoantibodies (GADA, IA-2A, and IAA) or those with high levels of a single antibody in both the screening and confirmation samples or in the screening sample plus a diagnosis of diabetes prior to obtaining the conformation sample. Presymptomatic type 1 diabetes will be classified as stage 1, 2, or 3: * Stage 1 will be defined as 2 or more islet autoantibodies or high levels of a single antibody and normal glucose tolerance based on OGTT results. (not including patients with only a single antibody who have first degree relative with type 1 diabetes) * Stage 2 will be defined as 1 or more islet autoantibodies accompanied by dysglycemia (fasting plasma glucose of 110-125 mg/dL or impaired 2-hour plasma glucose of 140- 199 mg/dL and/or plasma glucose ≥200 mg/dL at intermediate time points \[30, 60, 90 minutes\]) based on OGTT results. * Stage 3 will be defined according to the American Diabetes Association criteria

    Time frame: End of screening and follow-up period-4 years after obtaining the first screening test

  2. Frequency of Diabetic Ketoacidosis on the clinical presentation of Type 1 Diabetes

    Time frame: End of screening and follow-up period-4 years after obtaining the first screening test

Secondary outcomes

  1. The average age of islet autoantibody seroconversion

    Time frame: End of screening and follow-up period-4 years after obtaining the first screening test

  2. The rate of islet autoantibody seroconversion

    Time frame: End of screening and follow-up period-4 years after obtaining the first screening test

  3. The rate of progression from pre-symptomatic T1D to clinical diabetes

    Time frame: End of screening and follow-up period-4 years after obtaining the first screening test

07

Study locations

3 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Mar 2027, 71 months after the start.

Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 71 months is above that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2021
First posted
Apr 8, 2021
StartActual
Apr 1, 2021
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04834518
Collaborators
Juvenile Diabetes Research Foundation
Responsible party
Sponsor
First posted
Apr 8, 2021
Start date
Apr 1, 2021
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Oct 17, 2024

Study contacts

Moshe Phillip, Prof
Contact
moshe.phillip@phillipmd.com
972-544-795-995
Alona Hamou, MSc
Contact
alonah@clalit.org.il
972-545-950-277
Moshe Phillip, Prof
study director · Schneider Children's Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion